Shanghai ZJ Bio-Tech Co

Shanghai ZJ Bio-Tech Co Forward P/E

The Forward P/E Ratio of Shanghai ZJ Bio-Tech Co (688317.SS) as of Oct 29, 2026 is -117.24. In the previous year, Forward P/E Ratio was -31.55 — a change of 271.57% (lower).

Forward P/E

-117.24

YoY

271.57%

Last updated:

Forward P/E Ratio of Shanghai ZJ Bio-Tech Co is 2025 -117.24 . Forward P/E Ratio of Shanghai ZJ Bio-Tech Co was 2024 -31.55 . It decreases by 271.57% lower compared to the previous year.

The Shanghai ZJ Bio-Tech Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
64.54 CNY
Jan 1, 2019
78.06 CNY
Jan 1, 2020
4.32 CNY
Jan 1, 2021
5.30 CNY
Jan 1, 2022
5.29 CNY
Jan 1, 2023
-29.39 CNY
Jan 1, 2024
-31.55 CNY
Jan 1, 2025
-117.24 CNY
The Shanghai ZJ Bio-Tech Co Forward P/E history
YEARForward P/EYoY
-117.24+271.57%
-31.55+7.37%
-29.39-655.52%
5.29-0.23%
5.30+22.87%
4.32-94.47%
78.06+20.96%
64.54-17.30%
78.04-5.43%
82.52-33.27%
123.66+7.57%
114.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai ZJ Bio-Tech Co Stock analysis

What does Shanghai ZJ Bio-Tech Co do? Shanghai ZJ Bio-Tech Co., Ltd. generates revenue through the research, development, production, and sale of molecular diagnostic reagents and instruments. The company's primary products are nucleic acid detection kits and molecular diagnostic instruments, which are sold to customers in sectors including emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. The firm focuses its business activities within the domestic market, targeting institutions and organizations requiring diagnostic solutions for public health and clinical applications. The company's business model centers on providing diagnostic reagents and equipment for critical applications such as emergency public health safety and medical clinical diagnosis. Its products are designed to meet the needs of domestic customers in healthcare, public safety, and food safety sectors, with a strong emphasis on molecular diagnostics. Shanghai ZJ Bio-Tech leverages its domestic market presence to serve institutions requiring reliable diagnostic tools for health and safety monitoring. Shanghai ZJ Bio-Tech Co., Ltd. operates with a domestic market focus, selling its molecular diagnostic instruments and reagents to entities involved in public health, clinical diagnosis, and food safety. The firm's revenue streams are derived from the sale of nucleic acid detection kits and molecular diagnostic instruments, which are essential for applications in emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. Shanghai ZJ Bio-Tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai ZJ Bio-Tech Co stock

Forward P/E Ratio of Shanghai ZJ Bio-Tech Co is -117.24 in 2025.

Forward P/E Ratio of Shanghai ZJ Bio-Tech Co changed from -31.55 to -117.24, representing a 271.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Shanghai ZJ Bio-Tech Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Shanghai ZJ Bio-Tech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai ZJ Bio-Tech Co

All Key Metrics — Shanghai ZJ Bio-Tech Co